Overview

A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This study will measure the effectiveness and any side effects of LY317615 in participants with diffuse large B-cell lymphoma (DLBCL: a sub-type of Non-Hodgkins Lymphoma).
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company